CBI

Leading life science success

CBI is Israel’s largest life sciences holding company

about cbi

Clal Biotechnology Industries (TASE: CBI) is Israel’s leading life sciences investment company. CBI supports life sciences by identifying and powering science backed ventures and proactively guiding them to transform the healthcare industry.

portfolio

The CBI portfolio is comprised of biotechnology and medical device companies developing breakthrough solutions for serious unmet medical needs, while offering substantial value and investment potential.

+

MediWound

MediWound (Nasdaq: MDWD) is a specialty biotechnology company focused on the fields of severe burn and chronic wound management.
+

Gamida Cell

Gamida Cell is a cell and immune therapy visionary. Lead product, NiCord® is currently in phase III clinical trial in hematological malignancies.
+

Anchiano (formerly Biocancell)

Anchiano Therapeutics (TASE: ANCN) is a clinical stage biopharmaceutical company dedicated to developing new therapies for non-muscle-invasive bladder cancer.
+

Elicio

Elicio develops platform technologies to deliver agents directly to the antigen-presenting cells of the lymph nodes with many potential applications in cancer
+

Neon Therapeutics

Neon Therapeutics (Nasdaq: NTGN) is a clinical stage, immuno-oncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer.
+

Cadent Therapeutics

Cadent Therapeutics is developing novel drugs for neurological and psychiatric disorders.
+

Exithera

eXIthera Pharmaceuticals is a clinical stage biotech company focused on discovering and developing Factor XIa inhibitors for the prevention of stroke and thrombosis.
+

Biokine

Biokine Therapeutics is company focused on developing novel therapeutics to treat cancer. It's lead product, BL-8040, is licensed to BiolineRx and is in phase III clinical development.

See complete portfolio

Press Releases

2020

01

Jul

Elicio Therapeutics: Additional $6 Million Financing
30

Jun

MediWound: Submission of Biologics License Application to the US FDA for NexoBrid in the Treatment of Severe Thermal Burns
27

May

Gamida Cell: Full Exercise of Underwriters’ Option to Purchase Additional Shares
25

May

Gamida Cell: Additional Results from GDA-201’s Phase 1 Trial in Non-Hodgkin’s Lymphoma and Multiple Myeloma
19

May

Gamida Cell Announces Pricing of $60 Million Public Offering of Ordinary Shares
12

May

Gamida Cell: Positive Topline Data from Phase 3 Trial of Omidubicel in High-Risk Hematologic Malignancy Patients Requiring Marrow Transplant

Read all Press Releases